CARGO Therapeutics (CRGX) last traded on August 18, 2025. A Form 15-12G filed on August 29, 2025 ends the SEC registration of its shares.
What Changed
Price Move History
- Daily moves over 5%
- 41 251 sessions, August 16, 2024 to August 18, 2025
- Largest daily move
- -74.3% close of January 30, 2025
- 1-year change
- -73% closing prices, August 16, 2024 to August 18, 2025
- 1-month change
- -2.2% closing prices, July 18, 2025 to August 18, 2025
Company Description
Written before these shares stopped trading.
CARGO Therapeutics, Inc. (CRGX) was a clinical-stage biotechnology company whose work centered on the research and development of cell therapies for cancer patients. According to multiple company disclosures, CARGO described itself as a biotechnology company focused on, and positioned to advance, next-generation, potentially curative cell therapies that directly address limitations of approved cell therapies such as limited durability of effect, safety concerns and unreliable supply.
The company’s activities were classified under research and development in biotechnology within the broader professional, scientific, and technical services sector. CARGO’s public filings and press releases consistently characterize it as a clinical-stage biotechnology company with programs, platform technologies, and manufacturing strategy aimed at improving the performance and availability of cell therapies.
Core programs and therapeutic focus
CARGO’s lead program was firicabtagene autoleucel (firi-cel, also referenced as CRG-022), described as an autologous CD22 chimeric antigen receptor (CAR) T‑cell therapy candidate. Company communications state that firi-cel was evaluated in a potentially pivotal Phase 2 clinical study (FIRCE‑1) in patients with large B‑cell lymphoma (LBCL) whose disease relapsed or was refractory to CD19 CAR T‑cell therapy. CARGO reported that it exclusively in‑licensed the underlying CD22 CAR T‑cell technology from the National Cancer Institute and that Phase 1 data generated at Stanford Medicine supported further development.
Beyond its lead program, CARGO described a pipeline built on proprietary cell‑engineering platform technologies that incorporate multiple transgene therapeutic “cargo” to enhance CAR T‑cell persistence, trafficking to tumor lesions, and to help safeguard against tumor resistance and T‑cell exhaustion. This approach is highlighted in repeated company descriptions and forms the conceptual basis for its name and pipeline strategy.
A key pipeline asset was CRG‑023, which CARGO characterized as a CD19/CD20/CD22 tri‑specific CAR T product candidate. Company materials describe CRG‑023 as a first‑of‑its‑kind tri‑cistronic CAR T designed to express three independent CARs from a single vector, each with its own co‑stimulatory domain, including CD2 co‑stimulation. According to the company, CRG‑023 is intended to address several known causes of relapse associated with existing CAR T‑cell therapies, such as tumor antigen loss, loss of co‑stimulation and T‑cell exhaustion, with the goal of providing more patients with durable responses across a broad range of B‑cell malignancies.
CARGO also disclosed development of a novel allogeneic platform, described as a universal vector solution designed to limit immune‑based rejection and enable durable response of CAR T‑cell therapy. Company statements explain that this allogeneic‑enabling vector is intended to be paired with new or existing CAR vectors to create allogeneic CAR T‑cell therapies while leveraging existing autologous drug product processes, with the aim of maintaining efficacy, durability and safety while broadening availability to more people with cancer.
Scientific and operational capabilities
Across its public communications, CARGO emphasized its proprietary cell‑engineering platform technologies and internally developed processes and analytical methods. It highlighted capabilities in designing, developing and delivering oncology and cell therapy products, including manufacturing strategies intended to provide predictable and reliable drug product supply. The company reported strong manufacturing success for firi‑cel in its clinical program and described its lentiviral vector production for CRG‑023 as using a suspension culture process with a line of sight to commercially suitable expression levels.
CARGO also noted that its leadership, founders and team have significant experience in developing, engineering, manufacturing, launching and commercializing oncology and cell therapy products. The company repeatedly referenced expertise in CAR T‑cell therapy, including the use of multiple transgene “cargo” to enhance CAR T‑cell performance and to address mechanisms such as tumor resistance, T‑cell exhaustion, and immune‑based rejection.
Corporate status, merger and delisting
CARGO Therapeutics, Inc. was listed on The Nasdaq Stock Market LLC under the symbol CRGX. According to a Form 8‑K dated August 19, 2025, CARGO entered into an Agreement and Plan of Merger with Concentra Biosciences, LLC and Concentra Merger Sub VII, Inc. and completed a tender offer followed by a merger. The filing states that on August 19, 2025, Merger Sub merged with and into CARGO, with CARGO continuing as the surviving corporation and becoming a wholly owned subsidiary of Concentra.
The same Form 8‑K reports that, in connection with the consummation of the offer and merger, CARGO notified Nasdaq of the merger and requested suspension of trading of its common stock and the filing of a Form 25 to effect delisting and deregistration under Section 12(b) of the Exchange Act. A subsequent Form 25 (Form 25‑NSE) filed by Nasdaq identifies CARGO Therapeutics, Inc. and its common stock and serves as notification of removal from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934.
Following the Form 25, CARGO filed a Form 15‑12G, certifying termination of registration under Section 12(g) and suspension of duty to file reports under Sections 13 and 15(d) of the Exchange Act. The Form 15 notes that the approximate number of holders of record as of the certification date was one, consistent with CARGO’s status as a wholly owned subsidiary after completion of the merger.
These filings together indicate that CRGX has been delisted from Nasdaq and deregistered with the SEC as a reporting company, and that public reporting obligations for the common stock have been suspended. The ticker CRGX therefore represents a defunct public listing that historically corresponded to CARGO Therapeutics, Inc. prior to its acquisition by Concentra Biosciences.
Strategic review and pipeline changes prior to acquisition
Before the completion of the merger, CARGO disclosed a series of strategic shifts. In a March 18, 2025 corporate update, the company announced the discontinuation of the FIRCE‑1 Phase 2 study of firi‑cel and stated that its board had concluded it was in the best interests of shareholders to cease development operations. The same update reported suspension of development efforts for CRG‑023 and the allogeneic platform, along with a significant reduction in workforce and an intent to pursue a reverse merger or other business combination.
Earlier, on January 29, 2025, CARGO had announced its decision to discontinue FIRCE‑1 based on an ad hoc analysis of safety and efficacy data, while at that time indicating plans to continue advancing CRG‑023 and the allogeneic platform and to evaluate strategic options. Subsequent communications, including the March 18, 2025 update, clarified that development operations across these programs were being halted as part of a broader strategic review.
Historical context for investors and researchers
For investors, clinicians, and researchers reviewing CRGX as a historical listing, CARGO Therapeutics represents a case of a clinical‑stage biotechnology company that advanced differentiated CAR T‑cell and allogeneic platform concepts, conducted clinical and preclinical work in B‑cell malignancies, and then transitioned through a strategic review, suspension of development, and ultimately an acquisition by Concentra Biosciences. Its SEC filings and press releases provide a detailed record of its scientific rationale, clinical program design, and corporate actions leading up to its delisting and deregistration.
Stock Performance
CARGO Therapeutics (CRGX) closed at $4.47 on August 18, 2025. In the 12 months to August 18, 2025, the price lost 73.0%.
See what a $1,000 investment in CRGX was worth at its last close
CRGX Metrics & Rankings
Price returns through August 18, 2025. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
CARGO Therapeutics has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include acquisition, clinical trial, conferences, earnings. View all CRGX news →
SEC Filings
CARGO Therapeutics has filed 10 recent SEC filings, including 7 Form 4, 1 Form 15-12G, 1 Form SCHEDULE 13D/A, 1 Form 25-NSE. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all CRGX SEC filings →
Financial Highlights
CARGO Therapeutics reported operating income of -$187.4M in FY2024, and net income was -$167.5M. Diluted earnings per share stood at -$3.72. The company generated -$139.7M in operating cash flow. The current ratio was 13.79, measuring current assets divided by current liabilities.
Upcoming Events
CRGX Company Profile & Sector Positioning
CARGO Therapeutics (CRGX) operates in the Biotechnology industry within the broader Healthcare sector.
Investors comparing CRGX often look at related companies in the same sector, including Lyell Immunopharma, Inc. (LYEL), Immunome, Inc. (IMNM), Precigen, Inc. (PGEN), Inhibrx Biosciences, Inc. (INBX), and Century Therapeutics, Inc. (IPSC). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CRGX's relative position within its industry.